文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

经动脉化疗栓塞治疗肝细胞癌:2023 年韩国肝癌协会基于专家共识的实用推荐。

Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association.

机构信息

Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.

Department of Radiology, Seoul National University Hospital, Seoul, Korea.

出版信息

Clin Mol Hepatol. 2023 Jul;29(3):521-541. doi: 10.3350/cmh.2023.0202. Epub 2023 Jul 1.


DOI:10.3350/cmh.2023.0202
PMID:37482892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10366793/
Abstract

Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients with hepatocellular carcinoma (HCC) and was established as conventional TACE using Lipiodol in the 1980s. In the 2000s, drug-eluting beads were developed and applied clinically. Currently, TACE is a commonly used non-surgical treatment modality for patients with HCC who are unsuitable for curative treatment. Considering the vital role of TACE in the management of HCC, it is crucial to organize current knowledge and expert opinions regarding patient preparation, procedural techniques, and post-treatment care in TACE, which can enhance therapeutic efficacy and safety. A group of 12 experts in the fields of interventional radiology and hepatology, convened by the Research Committee of the Korean Liver Cancer Association (KLCA), has developed expert consensus-based practical recommendations in TACE. These recommendations have been endorsed by the Korean Society of Interventional Radiology and provide useful information and direction in performing TACE procedure as well as pre- and post- procedural patient care.

摘要

经肝动脉向肝癌(HCC)患者的明胶海绵颗粒中注入化疗药物的经动脉化疗栓塞术(TACE)于 1977 年问世,并于 20 世纪 80 年代采用碘油确立了常规 TACE。21 世纪,载药微球被开发并应用于临床。目前,TACE 是不适合根治性治疗的 HCC 患者常用的非手术治疗方法。考虑到 TACE 在 HCC 管理中的重要作用,有必要对患者准备、手术技术和 TACE 后护理方面的现有知识和专家意见进行组织,以提高治疗效果和安全性。由韩国肝癌协会(KLCA)研究委员会召集的 12 名介入放射学和肝病学领域的专家制定了 TACE 基于专家共识的实用建议。这些建议得到了韩国介入放射学会的认可,为 TACE 手术前、手术中和手术后的患者护理提供了有用的信息和指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e555/10366793/693cdf3a9c54/cmh-2023-0202f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e555/10366793/7ead97fde637/cmh-2023-0202f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e555/10366793/9281ff7ab80c/cmh-2023-0202f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e555/10366793/b02ffb285512/cmh-2023-0202f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e555/10366793/693cdf3a9c54/cmh-2023-0202f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e555/10366793/7ead97fde637/cmh-2023-0202f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e555/10366793/9281ff7ab80c/cmh-2023-0202f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e555/10366793/b02ffb285512/cmh-2023-0202f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e555/10366793/693cdf3a9c54/cmh-2023-0202f4.jpg

相似文献

[1]
Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association.

Clin Mol Hepatol. 2023-7

[2]
Transarterial Chemoembolization for Hepatocellular Carcinoma: 2023 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association.

Korean J Radiol. 2023-7

[3]
Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association.

J Liver Cancer. 2023-9

[4]
Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques.

Eur Radiol. 2018-10-22

[5]
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion.

Cardiovasc Intervent Radiol. 2015-9-21

[6]
CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.

World J Surg Oncol. 2018-3-27

[7]
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.

BMC Cancer. 2015-6-10

[8]
[Expert consensus on transarterial chemoembolization refractoriness and subsequent therapies in hepatocellular carcinoma].

Zhonghua Nei Ke Za Zhi. 2022-8-1

[9]
Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future.

Clin Mol Hepatol. 2015-12

[10]
Local Ablation for Hepatocellular Carcinoma: 2024 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association.

Korean J Radiol. 2024-9

引用本文的文献

[1]
Prognostic Role of Short-Chain Fatty Acid-Producing Gut Microbiota and Gut Microbial Dynamics in Patients with Hepatocellular Carcinoma Receiving Chemoembolization: A Prospective Study.

J Hepatocell Carcinoma. 2025-8-31

[2]
Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

J Gastrointest Cancer. 2025-7-23

[3]
Optimizing Yttrium-90 Radioembolization Dosimetry for Hepatocellular Carcinoma: A Korean Perspective.

Korean J Radiol. 2025-7

[4]
Optimizing TACE for Hepatocellular Carcinoma: The Impact of Intra-Arterial Contrast Enhanced Ultrasound.

Diagnostics (Basel). 2025-5-29

[5]
A risk prediction model for nausea and vomiting after TACE: a cross-sectional study.

BMC Gastroenterol. 2025-6-4

[6]
The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM.

Front Immunol. 2025-4-2

[7]
Hepatic arterial infusion chemotherapy versus transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.

Eur Radiol. 2025-4-11

[8]
Correspondence to letter to the editor on "Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis".

Clin Mol Hepatol. 2025-1

[9]
Research progress on machine algorithm prediction of liver cancer prognosis after intervention therapy.

Am J Cancer Res. 2024-9-25

[10]
Dexamethasone and N-acetylcysteine before transarterial chemoembolization in hepatocellular carcinoma: A Western perspective.

World J Gastroenterol. 2024-8-21

本文引用的文献

[1]
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.

J Liver Cancer. 2023-3

[2]
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Korean J Radiol. 2022-12

[3]
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.

Clin Mol Hepatol. 2022-10

[4]
Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302.

Liver Cancer. 2022-6-15

[5]
Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE).

Cardiovasc Intervent Radiol. 2022-10

[6]
Prophylactic Use of Antibiotics for Postsurgical Infection in c-TACE and DEB-TACE High-Risk Patients: A Case-Control Study.

J Healthc Eng. 2022-4-11

[7]
Clinical management of vascular lake during transarterial chemoembolization with CalliSpheres drug-eluting beads (DEBs) for the treatment of hepatocellular carcinoma.

Transl Cancer Res. 2020-4

[8]
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.

J Hepatol. 2022-3

[9]
Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study.

World J Clin Cases. 2021-10-26

[10]
Effect and Safety of Prophylactic Parecoxib for Pain Control of Transarterial Chemoembolization in Liver Cancer: A Single-Center, Parallel-Group, Randomized Trial.

J Am Coll Radiol. 2022-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索